Grupos de investigación Todos los grupos >>
UCM
Universidad Complutense de Madrid
Facultad de Medicina. Madrid
- Tamargo J, Le Heuzey JY, Mabo P Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide. Eur. J. Clin. Pharmacol. 2015; 71: 549-67
- Tamargo J, Caballero R, Delpón E Cancer chemotherapy and cardiac arrhythmias: a review. Drug Saf 2015; 38: 129-52
- Tamargo J, Duarte J, Ruilope LM New antihypertensive drugs under development. Curr. Med. Chem. 2015; 22: 305-42
- Daimi H, Lozano-Velasco E, Haj Khelil A, Chibani JB, Barana A, Amorós I, González de la Fuente M, Caballero R, Aranega A, Franco D Regulation of SCN5A by microRNAs: miR-219 modulates SCN5A transcript expression and the effects of flecainide intoxication in mice. Heart Rhythm 2015; 12: 1333-42
- Rosano GM, Lewis B, Agewall S, Wassmann S, Vitale C, Schmidt H, Drexel H, Patak A, Torp-Pedersen C, Kjeldsen KP, Tamargo J Gender differences in the effect of cardiovascular drugs: a position document of the Working Group on Pharmacology and Drug Therapy of the ESC. Eur. Heart J. 2015; 36: 2677-80
- Toral M, Gómez-Guzmán M, Jimenez R, Romero M, Zarzuelo MJ, Utrilla MP, Hermenegildo C, Cogolludo A, Perez-Vizcaino F, Gálvez J, Duarte J Chronic peroxisome proliferator-activated receptorβ/δ agonist GW0742 prevents hypertension, vascular inflammatory and oxidative status, and endothelial dysfunction in diet-induced obesity. J. Hypertens. 2015; 33: 1831-44
- López-Farré AJ, Rodríguez-Sierra P, Modrego J, Segura A, Martín-Palacios N, Saiz AM, Zamorano-León JJ, Duarte J, Serrano J, Moñux G Effects of factor Xa on the expression of proteins in femoral arteries from type 2 diabetic patients. Br J Clin Pharmacol 2014; 78: 1366-77
- Tamargo J, Caballero R, Delpón E New drugs for the treatment of hyperkalemia in patients treated with renin-angiotensin-aldosterone system inhibitors -- hype or hope? Discov Med 2014; 18: 249-54
- Tamargo J, Segura J, Ruilope LM Diuretics in the treatment of hypertension. Part 1: thiazide and thiazide-like diuretics. Expert Opin Pharmacother 2014; 15: 527-47
- Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galiè N, Gibbs JS, Huisman MV, Humbert M, Kucher N, Lang I, Lankeit M, Lekakis J, Maack C, Mayer E, Meneveau N, Perrier A, Pruszczyk P, Rasmussen LH, Schindler TH, Svitil P, Vonk Noordegraaf A, Zamorano JL, Zompatori M, Tamargo J 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur. Heart J. 2014; 35: 3033-69, 3069a-3069k
- Brignole M, Auricchio A, Barón-Esquivias G, Bordachar P, Boriani G, Breithardt OA, Cleland J, Deharo JC, Delgado V, Elliott PM, Gorenek B, Israel CW, Leclercq C, Linde C, Mont L, Padeletti L, Sutton R, Vardas PE, Tamargo J 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Rev Esp Cardiol (Engl Ed) 2014; 67: 58
- Toral M, Gómez-Guzmán M, Jimenez R, Romero M, Sánchez M, Utrilla MP, Garrido-Mesa N, Rodriguez-Cabezas ME, Olivares M, Gálvez J, Duarte J The probiotic Lactobacillus coryniformis CECT5711 reduces the vascular pro-oxidant and pro-inflammatory status in obese mice. Clin. Sci. 2014; 127: 33-45
- Gómez-Guzmán M, Jimenez R, Romero M, Sánchez M, Zarzuelo MJ, Gómez-Morales M, O'Valle F, López-Farré AJ, Algieri F, Gálvez J, Perez-Vizcaino F, Sabio JM, Duarte J Chronic hydroxychloroquine improves endothelial dysfunction and protects kidney in a mouse model of systemic lupus erythematosus. Hypertension 2014; 64: 330-7
- Barana A, Matamoros M, Dolz-Gaitón P, Pérez-Hernández M, Amorós I, Núñez M, Sacristán S, Pedraz A, Pinto A, Fernández-Avilés F, Tamargo J, Delpón E, Caballero R Chronic atrial fibrillation increases microRNA-21 in human atrial myocytes decreasing L-type calcium current. Circ Arrhythm Electrophysiol 2014; 7: 861-8
- Quintela AM, Jimenez R, Piqueras L, Gómez-Guzmán M, Haro J, Zarzuelo MJ, Cogolludo A, Sanz MJ, Toral M, Romero M, Perez-Vizcaino F, Duarte J PPARβ activation restores the high glucose-induced impairment of insulin signalling in endothelial cells. Br. J. Pharmacol. 2014; 171: 3089-102
- Ryden L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, Deaton C, Escaned J, Hammes HP, Huikuri H, Marre M, Marx N, Mellbin L, Ostergren J, Patrono C, Seferovic P, Uva MS, Taskinen MR, Tendera M, Tuomilehto J, Valensi P, Zamorano JL, Tamargo J ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - summary. Diab Vasc Dis Res 2014; 11: 133-73
- Tamargo J, Segura J, Ruilope LM Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents. Expert Opin Pharmacother 2014; 15: 605-21
- Gómez R, Caballero R, Barana A, Amorós I, De Palm SH, Matamoros M, Núñez M, Pérez-Hernández M, Iriepa I, Tamargo J, Delpón E Structural basis of drugs that increase cardiac inward rectifier Kir2.1 currents. Cardiovasc. Res. 2014; 104: 337-46
- Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Jüni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A, Tamargo J 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur. Heart J. 2014; 35: 2541-619
- Pérez A, González-Manzano S, Jimenez R, Perez-Abud R, Haro JM, Osuna A, Santos-Buelga C, Duarte J, Perez-Vizcaino F The flavonoid quercetin induces acute vasodilator effects in healthy volunteers: correlation with beta-glucuronidase activity. Pharmacol. Res. 2014; 89: 11-8
- Tamargo J, Solini A, Ruilope LM Comparison of agents that affect aldosterone action. Semin. Nephrol. 2014; 34: 285-306
- Gómez-Doblas JJ, Muñiz J, Martin JJ, Rodríguez-Roca G, Lobos JM, Awamleh P, Permanyer-Miralda G, Chorro FJ, Anguita M, Roig E Prevalence of atrial fibrillation in Spain. OFRECE study results. Rev Esp Cardiol (Engl Ed) 2014; 67: 259-69
- Duarte J, Francisco V, Perez-Vizcaino F Modulation of nitric oxide by flavonoids. Food Funct 2014; 5: 1653-68
- González de la Fuente M, Barana A, Gómez R, Amorós I, Dolz-Gaitón P, Sacristán S, Atienza F, Pita A, Pinto A, Fernández-Avilés F, Caballero R, Tamargo J, Delpón E Chronic atrial fibrillation up-regulates β1-Adrenoceptors affecting repolarizing currents and action potential duration. Cardiovasc. Res. 2013; 97: 379-88
- Brignole M, Auricchio A, Barón-Esquivias G, Bordachar P, Boriani G, Breithardt OA, Cleland J, Deharo JC, Delgado V, Elliott PM, Gorenek B, Israel CW, Leclercq C, Linde C, Mont L, Padeletti L, Sutton R, Vardas PE, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Blomstrom-Lundqvist C, Badano LP, Aliyev F, Bänsch D, Bsata W, Buser P, Charron P, Daubert JC, Dobreanu D, Faerestrand S, Le Heuzey JY, Mavrakis H, McDonagh T, Merino JL, Nawar MM, Nielsen JC, Pieske B, Poposka L, Ruschitzka F, Van Gelder IC, Wilson CM 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur. Heart J. 2013; 34: 2281-329
- Modrego J, Azcona L, Martín-Palacios N, Zamorano-León JJ, Segura A, Rodríguez P, Guerra R, Tamargo J, Macaya C, López-Farré AJ Platelet content of nitric oxide synthase 3 phosphorylated at Serine 1177 is associated with the functional response of platelets to aspirin. PLoS ONE 2013; 8: e82574
- Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 2013; 31: 1281-357
- Ryden L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, Deaton C, Escaned J, Hammes HP, Huikuri H, Marre M, Marx N, Mellbin L, Ostergren J, Patrono C, Seferovic P, Uva MS, Taskinen MR, Tendera M, Tuomilehto J, Valensi P, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Torbicki A, Wijns W, Windecker S, De Backer G, Ezquerra EA, Avogaro A, Badimon L, Baranova E, Betteridge J, Ceriello A, Funck-Brentano C, Gulba DC, Kjekshus JK, Lev E, Mueller C, Neyses L, Nilsson PM, Perk J, Reiner Z, Sattar N, Schächinger V, Scheen A, Schirmer H, Strömberg A, Sudzhaeva S, Viigimaa M, Vlachopoulos C, Xuereb RG ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur. Heart J. 2013; 34: 3035-87
- Zarzuelo MJ, López-Sepúlveda R, Sánchez M, Romero M, Gómez-Guzmán M, Ungvary Z, Perez-Vizcaino F, Jimenez R, Duarte J SIRT1 inhibits NADPH oxidase activation and protects endothelial function in the rat aorta: implications for vascular aging. Biochem. Pharmacol. 2013; 85: 1288-96
- Núñez L, Barana A, Amorós I, de la Fuente MG, Dolz-Gaitón P, Gómez R, Rodríguez-García I, Mosquera I, Monserrat L, Delpón E, Caballero R, Castro-Beiras A, Tamargo J p.D1690N Nav1.5 rescues p.G1748D mutation gating defects in a compound heterozygous Brugada syndrome patient. Heart Rhythm 2013; 10: 264-72
- Dolz-Gaitón P, Núñez M, Núñez L, Barana A, Amorós I, Matamoros M, Pérez-Hernández M, González de la Fuente M, Alvarez-López M, Macías-Ruiz R, Tercedor-Sánchez L, Jiménez-Jáimez J, Delpón E, Caballero R, Tamargo J Functional characterization of a novel frameshift mutation in the C-terminus of the Nav1.5 channel underlying a Brugada syndrome with variable expression in a Spanish family. PLoS ONE 2013; 8: e81493
- Amorós I, Dolz-Gaitón P, Gómez R, Matamoros M, Barana A, de la Fuente MG, Núñez M, Pérez-Hernández M, Moraleda I, Gálvez E, Iriepa I, Tamargo J, Caballero R, Delpón E Propafenone blocks human cardiac Kir2.x channels by decreasing the negative electrostatic charge in the cytoplasmic pore. Biochem. Pharmacol. 2013; 86: 267-78
- Zarzuelo MJ, Gómez-Guzmán M, Jimenez R, Quintela AM, Romero M, Sánchez M, Zarzuelo A, Tamargo J, Perez-Vizcaino F, Duarte J Effects of peroxisome proliferator-activated receptor-β activation in endothelin-dependent hypertension. Cardiovasc. Res. 2013; 99: 622-31
- Wann LS, Curtis AB, Ellenbogen KA, Estes NA, Ezekowitz MD, Jackman WM, January CT, Lowe JE, Page RL, Slotwiner DJ, Stevenson WG, Tracy CM, Fuster V, Rydén LE, Cannom DS, Crijns HJ, Halperin JL, Le Heuzey J, Kay GN, Olsson SB, Prystowsky EN, Tamargo JL Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation 2013; 127: 1916-26
- Rodríguez-Gómez I, Banegas I, Wangensteen R, Quesada A, Jimenez R, Gómez-Morales M, O'Valle F, Duarte J, Vargas F Influence of thyroid state on cardiac and renal capillary density and glomerular morphology in rats. J. Endocrinol. 2013; 216: 43-51
- Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Guyton RA, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Wann LS, Curtis AB, Ellenbogen KA, Estes NA, Ezekowitz MD, Jackman WM, January CT, Lowe JE, Page RL, Slotwiner DJ, Stevenson WG, Tracy CM, Fuster V, Rydén LE, Cannom DS, Crijns HJ, Le Heuzey JY, Kay GN, Olsson SB, Prystowsky EN, Tamargo JL, Wann S Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 2013; 61: 1935-44
- Gómez-Guzmán M, Jimenez R, Sánchez M, Zarzuelo MJ, Galindo P, Quintela AM, López-Sepúlveda R, Romero M, Tamargo J, Vargas F, Perez-Vizcaino F, Duarte J Epicatechin lowers blood pressure, restores endothelial function, and decreases oxidative stress and endothelin-1 and NADPH oxidase activity in DOCA-salt hypertension. Free Radic. Biol. Med. 2012; 52: 70-9
- López-Farré AJ, Zamorano-León JJ, Segura A, Mateos-Cáceres PJ, Modrego J, Rodríguez-Sierra P, Calatrava L, Tamargo J, Macaya C Plasma desmoplakin I biomarker of vascular recurrence after ischemic stroke. J. Neurochem. 2012; 121: 314-25
- Tamargo J, Capucci A, Mabo P Safety of flecainide. Drug Saf 2012; 35: 273-89
- Tamargo J, Caballero R, Delpón E Drug-induced atrial fibrillation. Expert Opin Drug Saf 2012; 11: 615-34
- Tamargo J, Caballero R, Delpón E Drug-induced atrial fibrillation: does it matter? Discov Med 2012; 14: 295-9
- Quintela AM, Jimenez R, Gómez-Guzmán M, Zarzuelo MJ, Galindo P, Sánchez M, Vargas F, Cogolludo A, Tamargo J, Perez-Vizcaino F, Duarte J Activation of peroxisome proliferator-activated receptor-β/-δ (PPARβ/δ) prevents endothelial dysfunction in type 1 diabetic rats. Free Radic. Biol. Med. 2012; 53: 730-41
- Tamargo J TGFβ3 mutations cause arrhythmogenic right ventricular dysplasia type 1 and open the door to understanding the biological role of TGFβ3 (where there's a will, there's a way). Cardiovasc. Res. 2012; 96: 188-90; discussion 191-4
- López-Sepúlveda R, Gómez-Guzmán M, Zarzuelo MJ, Romero M, Sánchez M, Quintela AM, Galindo P, O'Valle F, Tamargo J, Perez-Vizcaino F, Duarte J, Jimenez R Red wine polyphenols prevent endothelial dysfunction induced by endothelin-1 in rat aorta: role of NADPH oxidase. Clin. Sci. 2011; 120: 321-33
- Wann LS, Curtis AB, January CT, Ellenbogen KA, Lowe JE, Estes NA, Page RL, Ezekowitz MD, Slotwiner DJ, Jackman WM, Stevenson WG, Tracy CM, Fuster V, Rydén LE, Cannom DS, Le Heuzey JY, Crijns HJ, Olsson SB, Olsson S, Prystowsky EN, Halperin JL, Tamargo JL, Kay GN, Wann L, Jacobs AK, Anderson JL, Albert N, Hochman JS, Buller CE, Kushner FG, Creager MA, Ohman EM, Ettinger SM, Guyton RA, Tarkington LG, Yancy CW 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 123: 104-23
- Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Kay GN, Le Huezey JY, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann LS 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J. Am. Coll. Cardiol. 2011; 57: e101-98
- Amorós I, Jiménez-Jáimez J, Tercedor L, Barana A, Gómez R, de la Fuente MG, Dolz-Gaitón P, Alvarez M, Martínez-Espín E, Lorente JA, Melgares R, Tamargo J, Delpón E, Caballero R Functional effects of a missense mutation in HERG associated with type 2 long QT syndrome. Heart Rhythm 2011; 8: 463-70
- Wann LS, Curtis AB, Ellenbogen KA, Estes NA, Ezekowitz MD, Jackman WM, January CT, Lowe JE, Page RL, Slotwiner DJ, Stevenson WG, Tracy CM, Fuster V, Rydén LE, Cannom DS, Crijns HJ, Halperin JL, Kay GN, Le Heuzey JY, Olsson SB, Prystowsky EN, Tamargo JL, Jacobs AK, Anderson JL, Albert N, Creager MA, Ettinger SM, Guyton RA, Hochman JS, Kushner FG, Ohman EM, Yancy CW 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on Dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2011; 123: 1144-50
- Chinchilla A, Daimi H, Lozano-Velasco E, Dominguez JN, Caballero R, Delpón E, Tamargo J, Cinca J, Hove-Madsen L, Aranega AE, Franco D PITX2 insufficiency leads to atrial electrical and structural remodeling linked to arrhythmogenesis. Circ Cardiovasc Genet 2011; 4: 269-79
- Tamargo J, López-Farré A, Caballero R, Delpón E Dronedarone. Drugs Today 2011; 47: 109-33
- Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Kay GN, Le Huezey JY, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann LS, Smith SC, Priori SG, Estes NA, Ezekowitz MD, Jackman WM, January CT, Page RL, Slotwiner DJ, Stevenson WG, Tracy CM, Jacobs AK, Anderson JL, Albert N, Buller CE, Creager MA, Ettinger SM, Guyton RA, Hochman JS, Kushner FG, Ohman EM, Tarkington LG, Yancy CW 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2011; 123: e269-367
- Tamargo J, Lopez-Sendon J Novel therapeutic targets for the treatment of heart failure. Nat Rev Drug Discov 2011; 10: 536-55
- Tamargo J, Duarte J, Caballero R, Delpón E New therapeutic targets for the development of positive inotropic agents. Discov Med 2011; 12: 381-92
- Tamargo J, Caballero R, Delpón E Ranolazine: an antianginal drug with antiarrhythmic properties. Expert Rev Cardiovasc Ther 2011; 9: 815-27
- López-Farré AJ, Zamorano-León JJ, Azcona L, Modrego J, Mateos-Cáceres PJ, González-Armengol J, Villarroel P, Moreno-Herrero R, Rodríguez-Sierra P, Segura A, Tamargo J, Macaya C Proteomic changes related to "bewildered" circulating platelets in the acute coronary syndrome. Proteomics 2011; 11: 3335-48
- Wann LS, Curtis AB, January CT, Ellenbogen KA, Lowe JE, Estes NA, Page RL, Ezekowitz MD, Slotwiner DJ, Jackman WM, Stevenson WG, Tracy CM, Fuster V, Rydén LE, Cannom DS, Le Heuzey JY, Crijns HJ, Olsson SB, Olsson S, Prystowsky EN, Halperin JL, Tamargo JL, Kay GN, Jacobs AK, Anderson JL, Albert N, Hochman JS, Buller CE, Kushner FG, Creager MA, Ohman EM, Ettinger SM, Guyton RA, Tarkington LG, Yancy CW 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Heart Rhythm 2011; 8: 157-76
- Zarzuelo MJ, Jimenez R, Galindo P, Sánchez M, Nieto A, Romero M, Quintela AM, López-Sepúlveda R, Gómez-Guzmán M, Bailón E, Rodríguez-Gómez I, Zarzuelo A, Gálvez J, Tamargo J, Perez-Vizcaino F, Duarte J Antihypertensive effects of peroxisome proliferator-activated receptor-β activation in spontaneously hypertensive rats. Hypertension 2011; 58: 733-43
- Aliot E, Capucci A, Crijns HJ, Goette A, Tamargo J Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation. Europace 2011; 13: 161-73
- Wann LS, Curtis AB, January CT, Ellenbogen KA, Lowe JE, Estes NA, Page RL, Ezekowitz MD, Slotwiner DJ, Jackman WM, Stevenson WG, Tracy CM, Fuster V, Rydén LE, Cannom DS, Le Heuzey JY, Crijns HJ, Olsson SB, Prystowsky EN, Halperin JL, Tamargo JL, Kay GN, Jacobs AK, Anderson JL, Albert N, Hochman JS, Buller CE, Kushner FG, Creager MA, Ohman EM, Ettinger SM, Guyton RA, Tarkington LG, Yancy CW 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 2011; 57: 223-42
- Prystowsky EN, Camm J, Lip GY, Allessie M, Bergmann JF, Breithardt G, Brugada J, Crijns H, Ellinor PT, Mark D, Naccarelli G, Packer D, Tamargo J The impact of new and emerging clinical data on treatment strategies for atrial fibrillation. J. Cardiovasc. Electrophysiol. 2010; 21: 946-58
- Amorós I, Barana A, Caballero R, Gómez R, Osuna L, Lillo MP, Tamargo J, Delpón E Endocannabinoids and cannabinoid analogues block human cardiac Kv4.3 channels in a receptor-independent manner. J. Mol. Cell. Cardiol. 2010; 48: 201-10
- Caballero R, de la Fuente MG, Gómez R, Barana A, Amorós I, Dolz-Gaitón P, Osuna L, Almendral J, Atienza F, Fernández-Avilés F, Pita A, Rodríguez-Roda J, Pinto A, Tamargo J, Delpón E In humans, chronic atrial fibrillation decreases the transient outward current and ultrarapid component of the delayed rectifier current differentially on each atria and increases the slow component of the delayed rectifier current in both. J. Am. Coll. Cardiol. 2010; 55: 2346-54
- Farré AJ, Tamargo J, Mateos-Cáceres PJ, Azcona L, Macaya C Old and new molecular mechanisms associated with platelet resistance to antithrombotics. Pharm. Res. 2010; 27: 2365-73
- Tamargo J, Duarte J, Caballero R, Delpón E Cinaciguat, a soluble guanylate cyclase activator for the potential treatment of acute heart failure. Curr Opin Investig Drugs 2010; 11: 1039-47
- Tamargo J, Tamarg J, Amorós I, Barana A, Caballero R, Delpón E New investigational drugs for the management of acute heart failure syndromes. Curr. Med. Chem. 2010; 17: 363-90
- Barana A, Amorós I, Caballero R, Gómez R, Osuna L, Lillo MP, Blázquez C, Guzmán M, Delpón E, Tamargo J Endocannabinoids and cannabinoid analogues block cardiac hKv1.5 channels in a cannabinoid receptor-independent manner. Cardiovasc. Res. 2010; 85: 56-67
- Caballero R, Dolz-Gaitón P, Gómez R, Amorós I, Barana A, González de la Fuente M, Osuna L, Duarte J, López-Izquierdo A, Moraleda I, Gálvez E, Sánchez-Chapula JA, Tamargo J, Delpón E Flecainide increases Kir2.1 currents by interacting with cysteine 311, decreasing the polyamine-induced rectification. Proc. Natl. Acad. Sci. U.S.A. 2010; 107: 15631-6
- Tamargo J, Caballero R, Gómez R, Delpón E Cardiac electrophysiological effects of nitric oxide. Cardiovasc. Res. 2010; 87: 593-600
- Romero M, Jimenez R, Hurtado B, Moreno JM, Rodríguez-Gómez I, López-Sepúlveda R, Zarzuelo A, Perez-Vizcaino F, Tamargo J, Vargas F, Duarte J Lack of beneficial metabolic effects of quercetin in adult spontaneously hypertensive rats. Eur. J. Pharmacol. 2010; 627: 242-50
- Romero M, Jimenez R, Sánchez M, López-Sepúlveda R, Zarzuelo A, Tamargo J, Perez-Vizcaino F, Duarte J Vascular superoxide production by endothelin-1 requires Src non-receptor protein tyrosine kinase and MAPK activation. Atherosclerosis 2010; 212: 78-85
- Modrego J, Maroto L, Tamargo J, Azcona L, Mateos-Cáceres P, Segura A, Moreno-Herrero R, Perez-Castellanos N, Delpón E, Pérez-Villacastín J, Rodríguez E, Macaya C, López-Farré AJ Comparative expression of proteins in left and right atrial appendages from patients with mitral valve disease at sinus rhythm and atrial fibrillation. J. Cardiovasc. Electrophysiol. 2010; 21: 859-68
- Burashnikov E, Pfeiffer R, Barajas-Martinez H, Delpón E, Hu D, Desai M, Borggrefe M, Häissaguerre M, Kanter R, Pollevick GD, Guerchicoff A, Laiño R, Marieb M, Nademanee K, Nam GB, Robles R, Schimpf R, Stapleton DD, Stapleton DH, Viskin S, Winters S, Wolpert C, Zimmern S, Veltmann C, Antzelevitch C Mutations in the cardiac L-type calcium channel associated with inherited J-wave syndromes and sudden cardiac death. Heart Rhythm 2010; 7: 1872-82
- Tamargo J, Delpón E Vagal stimulation and atrial electrical remodeling. Rev Esp Cardiol 2009; 62: 729-32
- Tamargo J, Caballero R, Gómez R, Delpón E I(Kur)/Kv1.5 channel blockers for the treatment of atrial fibrillation. Expert Opin Investig Drugs 2009; 18: 399-416
- Gómez R, Caballero R, Barana A, Amorós I, Calvo E, López JA, Klein H, Vaquero M, Osuna L, Atienza F, Almendral J, Pinto A, Tamargo J, Delpón E Nitric oxide increases cardiac IK1 by nitrosylation of cysteine 76 of Kir2.1 channels. Circ. Res. 2009; 105: 383-92
- Tamargo J, Caballero R, Gómez R, Barana A, Amorós I, Delpón E Investigational positive inotropic agents for acute heart failure. Cardiovasc Hematol Disord Drug Targets 2009; 9: 193-205
- Perez-Vizcaino F, Duarte J, Jimenez R, Santos-Buelga C, Osuna A Antihypertensive effects of the flavonoid quercetin. Pharmacol Rep 2009; 61: 67-75
- Delpón E, Cordeiro JM, Núñez L, Thomsen PE, Guerchicoff A, Pollevick GD, Wu Y, Kanters JK, Larsen CT, Hofman-Bang J, Burashnikov E, Christiansen M, Antzelevitch C Functional effects of KCNE3 mutation and its role in the development of Brugada syndrome. Circ Arrhythm Electrophysiol 2008; 1: 209-18
- Radicke S, Vaquero M, Caballero R, Gómez R, Núñez L, Tamargo J, Ravens U, Wettwer E, Delpón E Effects of MiRP1 and DPP6 beta-subunits on the blockade induced by flecainide of Kv4.3/KChIP2 channels. Br. J. Pharmacol. 2008; 154: 774-86
- Marrugat J, López-López JR, Heras M, Tamargo J, Valverde M, Valverde MA [The HERACLES Cardiovascular Network]. Rev Esp Cardiol 2008; 61: 66-75
- Gómez R, Núñez L, Vaquero M, Amorós I, Barana A, de Prada T, Macaya C, Maroto L, Rodríguez E, Caballero R, López-Farré A, Tamargo J, Delpón E Nitric oxide inhibits Kv4.3 and human cardiac transient outward potassium current (Ito1). Cardiovasc. Res. 2008; 80: 375-84
- Vaquero M, Calvo D, Jalife J Cardiac fibrillation: from ion channels to rotors in the human heart. Heart Rhythm 2008; 5: 872-9
- de la Sierra A, Gorostidi M, Marín R, Redon J, Banegas JR, Armario P, García Puig J, Zarco J, Llisterri JL, Sanchís C, Abarca B, Palomo V, Gomis R, Otero A, Villar F, Honorato J, Tamargo J, Lobos JM, Macías-Núñez J, Sarría A, Aranda P, Ruilope LM [Evaluation and management of hypertension in Spain. A consensus guide]. Med Clin (Barc) 2008; 131: 104-16
- Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, Dallongeville J, De Backer G, Ebrahim S, Gjelsvik B, Herrmann-Lingen C, Hoes A, Humphries S, Knapton M, Perk J, Priori SG, Pyorala K, Reiner Z, Ruilope L, Sans-Menendez S, Scholte op Reimer W, Weissberg P, Wood D, Yarnell J, Zamorano JL, Walma E, Fitzgerald T, Cooney MT, Dudina A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Funck-Brentano C, Filippatos G, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Altiner A, Bonora E, Durrington PN, Fagard R, Giampaoli S, Hemingway H, Hakansson J, Kjeldsen SE, Larsen ML, Mancia G, Manolis AJ, Orth-Gomer K, Pedersen T, Rayner M, Ryden L, Sammut M, Schneiderman N, Stalenhoef AF, Tokgözoglu L, Wiklund O, Zampelas A European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur. Heart J. 2007; 28: 2375-414
- Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosion E, Lindholm LH, Manolis A, Nilsson PM, Redon J, Viigimaa M, Adamopoulos S, Bertomeu V, Clement D, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, O'Brien E, Ponikowski P, Ruschitzka F, Tamargo J, van Zwieten P, Waeber B, Williams B [ESH/ESC 2007 Guidelines for the management of arterial hypertension]. Rev Esp Cardiol 2007; 60: 968.e1-94
- Vahanian A, Baumgartner H, Bax J, Butchart E, Dion R, Filippatos G, Flachskampf F, Hall R, Iung B, Kasprzak J, Nataf P, Tornos P, Torracca L, Wenink A Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur. Heart J. 2007; 28: 230-68
- Vera R, Sánchez M, Galisteo M, Villar IC, Jimenez R, Zarzuelo A, Perez-Vizcaino F, Duarte J Chronic administration of genistein improves endothelial dysfunction in spontaneously hypertensive rats: involvement of eNOS, caveolin and calmodulin expression and NADPH oxidase activity. Clin. Sci. 2007; 112: 183-91
- Moreno L, Frazziano G, Cogolludo A, Cobeño L, Tamargo J, Perez-Vizcaino F Role of protein kinase Czeta and its adaptor protein p62 in voltage-gated potassium channel modulation in pulmonary arteries. Mol. Pharmacol. 2007; 72: 1301-9
- Mansia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Struijker Boudier HA, Zanchetti A 2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood Press. 2007; 16: 135-232
- Vaquero M, Caballero R, Gómez R, Núñez L, Tamargo J, Delpón E Effects of atorvastatin and simvastatin on atrial plateau currents. J. Mol. Cell. Cardiol. 2007; 42: 931-45
- Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Zamorano JL, Smith SC, Jacobs AK, Adams CD, Anderson JL, Antman EM, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B [ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--excutive summary]. Rev Port Cardiol 2007; 26: 383-446
- Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Struijker Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Manolis A, Nilsson PM, Redon J, Struijker-Boudier HA, Viigimaa M, Adamopoulos S, Bertomeu V, Clement D, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, O'Brien E, Ponikowski P, Ruschitzka F, Tamargo J, van Zwieten P, Waeber B, Williams B 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J. 2007; 28: 1462-536
- [ACC/AHA/ESC 2006 guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death--executive summary]. Rev Port Cardiol 2007; 26: 883-937
- Vahanian A, Baumgartner H, Bax J, Butchart E, Dion R, Filippatos G, Flachskampf F, Hall R, Iung B, Kasprzak J, Nataf P, Tornos P, Torracca L, Wenink A [Guidelines on the management of valvular heart disease]. Rev Esp Cardiol 2007; 60: 1e-50e
- Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos S, Bertomeu V, Clement D, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O'Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Waeber B, Williams B 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 2007; 25: 1105-87
- Tamargo J, Caballero R, Núñez L, Gómez R, Vaquero M, Delpón E Genetically engineered mice as a model for studying cardiac arrhythmias. Front. Biosci. 2007; 12: 22-38
- Sánchez M, Lodi F, Vera R, Villar IC, Cogolludo A, Jimenez R, Moreno L, Romero M, Tamargo J, Perez-Vizcaino F, Duarte J Quercetin and isorhamnetin prevent endothelial dysfunction, superoxide production, and overexpression of p47phox induced by angiotensin II in rat aorta. J. Nutr. 2007; 137: 910-5
- Tamargo J, Caballero R, Gómez R, Núñez L, Vaquero M, Delpón E Lipid-lowering therapy with statins, a new approach to antiarrhythmic therapy. Pharmacol. Ther. 2007; 114: 107-26
- Cogolludo A, Frazziano G, Briones AM, Cobeño L, Moreno L, Lodi F, Salaices M, Tamargo J, Perez-Vizcaino F The dietary flavonoid quercetin activates BKCa currents in coronary arteries via production of H2O2. Role in vasodilatation. Cardiovasc. Res. 2007; 73: 424-31
- Alonso-Orgaz S, Moreno L, Macaya C, Rico L, Mateos-Cáceres PJ, Sacristán D, Perez-Vizcaino F, Segura A, Tamargo J, López-Farré A Proteomic study of plasma from moderate hypercholesterolemic patients. J. Proteome Res. 2006; 5: 2301-8
- Núñez L, Vaquero M, Gómez R, Caballero R, Mateos-Cáceres P, Macaya C, Iriepa I, Gálvez E, López-Farré A, Tamargo J, Delpón E Nitric oxide blocks hKv1.5 channels by S-nitrosylation and by a cyclic GMP-dependent mechanism. Cardiovasc. Res. 2006; 72: 80-9
Coordinador
Miembros
- Irene Amorós
- Adriana Barana
- Ricardo Caballero
- Eva Delpón
- Juan M. Duarte
- Raquel García Utrilla
- Marta González de la Fuente
- Manuel Gómez
- Rosario Jiménez
- Marcos Matamoros
- Mercedes Núñez Lozano
- Sandra Sacristán
- Marta Pérez-Hernández
- Lorena Ondo Martín
- Miguel Romero Pérez
- Paloma Vaquero
- David Tinaquero Faura
Una iniciativa de
